AlconXSWX:ALCE +3.65%53 PS Ratio is 3.24 as of Jun. 25, 2026, which is 21% below its 10-year median of 4.11. GuruFocus rates XSWX:ALCE with a GF Score™ of 53/100 and a GF Value™ of CHF73.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Alcon ranks worse than 54.48% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Alcon's share price is CHF55.60.
Alcon's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF17.18. Hence, Alcon's PS Ratio for today is 3.24.
The historical rank and industry rank for Alcon's PS Ratio or its related term are showing as below:
XSWX:ALCE'
s PS Ratio Range Over the Past 10 Years
Min: 2.85 Med: 4.11 Max: 5.41
Current: 3.22
During the past 10 years, Alcon's highest PS Ratio was 5.41. The lowest was 2.85. And the median was 4.11.
XSWX:ALCE's PS Ratio is ranked worse than 54.48% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.865
vs XSWX:ALCE: 3.22
Alcon's Revenue per Sharefor the
three
months ended in Mar. 2026 was CHF4.35.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF17.18.
Warning Sign:
Alcon Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Alcon was -2.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.60% per year.
During the past 10 years, Alcon's highest 3-Year average Revenue per Share Growth Rate was 9.90% per year. The lowest was -3.30% per year. And the median was 2.80% per year.
Back to Basics: PS Ratio
Alcon (XSWX:ALCE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Alcon PS Ratio Related Terms
Alcon PS Ratio Historical Data
* Premium members only.
The historical data trend for Alcon's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Alcon's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's PS Ratio distribution charts can be found below:
* The bar in red indicates where Alcon's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Alcon's Share Price of today is CHF55.60. Alcon's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF17.18.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Alcon (XSWX:ALCE) has a PS Ratio of 3.24 as of Jun. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Alcon and its competitors. This is 21% below median its historical median of 4.11. Over the past decade, Alcon's PS Ratio has ranged from 2.85 to 5.41. According to the industry distribution chart, Alcon ranks #438 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 54.5%.
Is Alcon's PS Ratio too high?
Alcon's current PS Ratio of 3.24 is 21% below median its 10-year median of 4.11. Over the past 10 years, this metric has ranged from a low of 2.85 to a high of 5.41. The Medical Devices & Instruments industry median PS Ratio is 2.87. Alcon's value of 3.24 is 13.1% above this industry median. Based on the distribution chart, Alcon ranks #438 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alcon has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #438 out of 804 companies for PS Ratio. This places Alcon in the lower half of its industry. The industry median PS Ratio is 2.87. Alcon's value of 3.24 is 13.1% above this benchmark. Historically, Alcon's own PS Ratio has ranged from 2.85 to 5.41 over the past decade. While the company's 10-year median is 4.11 vs. the industry median of 2.87, Alcon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.87, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcon's current PS Ratio of 3.24 is 13.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Alcon and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current PS Ratio is 3.24, which is 21% below median its own 10-year median of 4.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALCE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF73.46, compared to a current price of CHF55.60 — trading 24.3% below its estimated fair value. The current PS Ratio is 3.24, which is 21% below median its 10-year median of 4.11 and 13.1% above the Medical Devices & Instruments industry median of 2.87. Alcon's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Alcon (XSWX:ALCE), the current PS Ratio is 3.24 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (XSWX:ALCE) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of CHF55.60 is trading 24.3% below its estimated GF Value™ of CHF73.46.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for XSWX:ALCE:
PS Ratio: 3.24 (21% below median its 10-year median of 4.11)
GF Value™: CHF73.46 vs. price of CHF55.60 (24.3% below fair value)
Industry Position: 13.1% above the Medical Devices & Instruments median (#438 of 804)
No single metric tells the full story. See the XSWX:ALCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
53GF Score
Get the complete analysis for XSWX:ALCE
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ALCE has been successfully added to your 
